id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-307660-onz6vfre	Titanji, Boghuma K	Use of Baricitinib in Patients with Moderate and Severe COVID-19	2020-06-29		.txt	text/plain	1084	75	51	Coronavirus Infectious Disease-19 (COVID-19), caused by Severe Acute Respiratory Virus Syndrome Coronavirus-2 (SARS-CoV-2) has led to over 8 million confirmed infections worldwide with an estimated global mortality of 5.6% as of June 17 th 2020 1 . Patients had laboratory confirmed COVID-19, diagnosed by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) testing of oropharyngeal, nasopharyngeal or tracheal aspirate samples and were treated at the discretion of the medical team with a combination of hydroxychloroquine and baricitinib if they fulfilled at least one of the following criteria: 1) evidence of pneumonia on lung imaging and requiring supplemental oxygen on admission or development of a new oxygen requirement during the course of their hospitalization 2) moderate disease requiring hospitalization (e.g., severe diarrhea requiring volume resuscitation, encephalopathy, evidence of end-A c c e p t e d M a n u s c r i p t organ damage); 3) elevated or rising inflammatory markers during hospitalization.	./cache/cord-307660-onz6vfre.txt	./txt/cord-307660-onz6vfre.txt